Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Stem Cells. Apr 26, 2026; 18(4): 116829
Published online Apr 26, 2026. doi: 10.4252/wjsc.v18.i4.116829
Published online Apr 26, 2026. doi: 10.4252/wjsc.v18.i4.116829
Phytocannabinoid-induced priming and differentiation of mesenchymal stem cells: Therapeutic potential
Lucas Vinícius de Oliveira Ferreira, Pedro Henrique Domingues de Oliveira, Rogério Martins Amorim, Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University, Botucatu 18618-681, São Paulo, Brazil
Lucas Vinícius de Oliveira Ferreira, Pedro Henrique Domingues de Oliveira, Rogério Martins Amorim, Center for Translational Research in Regenerative Medicine, Institute of Biotechnology, São Paulo State University, Botucatu 18607-440, São Paulo, Brazil
Author contributions: Ferreira LVO, de Oliveira PHD, and Amorim RM prepared and wrote the manuscript, and made equal contributions to this study; and all authors have read and approved the final manuscript.
Supported by the Doctoral Scholarship granted by the São Paulo Research Foundation (FAPESP), No. 2024/19980-0.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Rogério Martins Amorim, Associate Professor, Department of Veteri
Received: November 21, 2025
Revised: December 27, 2025
Accepted: February 9, 2026
Published online: April 26, 2026
Processing time: 150 Days and 14 Hours
Revised: December 27, 2025
Accepted: February 9, 2026
Published online: April 26, 2026
Processing time: 150 Days and 14 Hours
Core Tip
Core Tip: Phytocannabinoids have emerged as promising modulators of mesenchymal stem cell (MSC) behavior, influencing immunomodulation and differentiation. Although a few in vivo studies exist, the majority of evidence comes from in vitro models. However, challenges remain for the clinical application of MSC priming with phytocannabinoids or the secretome derived from primed cells. Standardized priming protocols, deeper mechanistic insights, and comprehensive in vivo validation are crucial to fully harness their therapeutic potential.